{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:12:25Z","timestamp":1782299545987,"version":"3.54.5"},"reference-count":25,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T00:00:00Z","timestamp":1407801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>B cells drive antibody formation and T cell activation. This study aimed to describe the clinical indications, efficacy and adverse events (AEs) for the B-cell depleting agent, rituximab, in a large cohort of children with lupus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prescribing records and the UK JSLE Cohort Study database identified rituximab use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-three patients received 104 courses of intravenous rituximab over a 10-year period. Patients were aged 12.2 (IQR 9.0\u201313.9) years at diagnosis and 50 (79%) were female. They had disease for 1.4 (0.2\u20133.0) years at the time of rituximab. Lupus nephritis was the most common indication (36% of first courses). Clinical biomarkers, 2.5 (1.6\u20134.3) months after treatment, demonstrated a statistically significant improvement in ESR, C3, C4, creatinine, albumin, haemoglobin, anti-dsDNA titres and urine albumin:creatinine ratio. IgG, IgA and IgM levels decreased ( p\u2009&lt;\u20090.01). Oral corticosteroid dose significantly reduced after rituximab (dose before 0.26 (0.09\u20130.44) mg\/kg, after 0.17 (0.09\u20130.30) mg\/kg; p\u2009=\u20090.01)). AEs occurred in 19 (18%) of all courses including; delayed second dose (8%), Ig replacement (2%) and infusion reactions (6%; anaphylaxis 2%). The global BILAG score showed a trend toward improvement (before 4.5 (2.0\u20139.0), after 3.0 (2.0\u20135.0); p\u2009=\u20090.16).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rituximab improves disease activity in children with lupus and serious AEs are infrequent. Controlled studies are required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0961203314547793","type":"journal-article","created":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T09:53:26Z","timestamp":1407923606000},"page":"10-17","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":74,"title":["The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE"],"prefix":"10.1177","volume":"24","author":[{"given":"L","family":"Watson","sequence":"first","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Institute of Translational Medicine, University of Liverpool, UK"},{"name":"Department of Paediatric Nephrology, Alder Hey Children\u2019s NHS Foundation Trust Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M W","family":"Beresford","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Institute of Translational Medicine, University of Liverpool, UK"},{"name":"Department of Paediatric Rheumatology, Alder Hey Children\u2019s NHS Foundation Trust Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Maynes","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pilkington","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S D","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Glackin","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Tullus","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,8,12]]},"reference":[{"key":"bibr1-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000130285.72309.ab"},{"key":"bibr2-0961203314547793","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100729"},{"key":"bibr3-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313502863"},{"key":"bibr4-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307087875"},{"key":"bibr5-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1002\/art.34410"},{"key":"bibr6-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313503912"},{"key":"bibr7-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.009"},{"key":"bibr8-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1002\/art.27541"},{"key":"bibr9-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"bibr10-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233"},{"key":"bibr11-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1387-5"},{"key":"bibr12-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"bibr13-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1002\/art.34410"},{"key":"bibr14-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh624"},{"key":"bibr15-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"bibr16-0961203314547793","unstructured":"British Society for Paediatric and Adolescent Rheumatology. BSPAR guidance for rituximab, http:\/\/wwwbspar.org.uk\/clinical-guidelines (accessed 16 December 2013)."},{"key":"bibr17-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1002\/art.21351"},{"key":"bibr18-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2013.816479"},{"key":"bibr19-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312474084"},{"key":"bibr20-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2009.01988.x"},{"key":"bibr21-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2010.01771.x"},{"key":"bibr22-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1002\/art.23204"},{"key":"bibr23-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2094-1"},{"key":"bibr24-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq436"},{"key":"bibr25-0961203314547793","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312446627"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0961203314547793","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0961203314547793","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0961203314547793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:14:58Z","timestamp":1777677298000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0961203314547793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,12]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1177\/0961203314547793"],"URL":"https:\/\/doi.org\/10.1177\/0961203314547793","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,12]]}}}